Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients who are at least 6 years of age, and who will not have reached their 18th birthday~* Diagnosis of ADHD and presence of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria A through C for ODD (NOTE: diagnosis for conduct disorder not exclusionary)~* Normal intelligence~* Able to swallow capsules~Exclusion Criteria:~* Weigh less than 20 kilogram (kg) or more than 90 kg at study entry~* Prior treatment with atomoxetine~* History of seizure disorder, suicidal risk, alcohol or drug abuse within the past 3 months~* History of severe allergies or multiple adverse drug reactions~* Cardiovascular disorders: hypertension, unexplained cardiac signs or symptoms, QT (measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle) prolongation , inherited cardiac disorders

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine Fast Titration (Type: EXPERIMENTAL): 0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks
- Atomoxetine Slow Titration (Type: EXPERIMENTAL): 0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo daily dose taken orally

Based on this trial design, predict the completion outcome and termination type (if applicable).